金黄色葡萄球菌菌血症的抗血小板治疗：过去的时光并非一无是处？
Antiplatelet Therapy in Staphylococcus aureus Bacteremia: No Time Like the Past?
机构信息
Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA.
Duke Clinical Research Institute, Durham, North Carolina, USA.
出版信息
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0036522. doi: 10.1128/aac.00365-22. Epub 2022 May 10.
Abstract
In this invited commentary, we reflect on the accompanying study by A. R. Caffrey, H. J. Appaneal, K. L. LaPlante, V. V. Lopes, et al. (Antimicrob Agents Chemother 66:e02117-21, 2022, https://doi.org/10.1128/aac.02117-21), which analyzed the impact of clopidogrel use on clinical outcomes in Staphylococcus aureus bacteremia.
摘要
在这篇特邀评论中，我们对 A. R. Caffrey、H. J. Appaneal、K. L. LaPlante、V. V. Lopes 等人的伴随研究进行了反思（Antimicrob Agents Chemother 66:e02117-21，2022，https://doi.org/10.1128/aac.02117-21），该研究分析了氯吡格雷在金黄色葡萄球菌菌血症中的使用对临床结果的影响。
相似文献
1
Antiplatelet Therapy in Staphylococcus aureus Bacteremia: No Time Like the Past?金黄色葡萄球菌菌血症的抗血小板治疗：过去的时光并非一无是处？
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0036522. doi: 10.1128/aac.00365-22. Epub 2022 May 10.
2
Ticagrelor Increases Platelet-Mediated Staphylococcus aureus Killing, Resulting in Clearance of Bacteremia.替卡格雷增加血小板介导的金黄色葡萄球菌杀伤作用，从而清除菌血症。
J Infect Dis. 2021 Nov 16;224(9):1566-1569. doi: 10.1093/infdis/jiab146.
3
Antiplatelet therapy for Staphylococcus aureus bacteremia: Will it stick?金黄色葡萄球菌菌血症的抗血小板治疗：它会有效吗？
PLoS Pathog. 2022 Feb 10;18(2):e1010240. doi: 10.1371/journal.ppat.1010240. eCollection 2022 Feb.
4
Management of bacteremia in adults.成人菌血症的管理
CMAJ. 2019 Sep 3;191(35):E967. doi: 10.1503/cmaj.190363.
5
[Outpatient parenteral antimicrobial therapy for Staphylococcus aureus bacteremia].金黄色葡萄球菌菌血症的门诊胃肠外抗菌治疗
Med Clin (Barc). 2011 Nov 26;137(14):663-4. doi: 10.1016/j.medcli.2011.03.005. Epub 2011 May 4.
6
Role of high vancomycin minimum inhibitory concentration in the outcome of methicillin-susceptible Staphylococcus aureus bacteremia.高万古霉素最低抑菌浓度在甲氧西林敏感金黄色葡萄球菌菌血症转归中的作用
J Infect Dis. 2012 Mar 15;205(6):1024-5. doi: 10.1093/infdis/jir870. Epub 2012 Jan 18.
7
Cefazolin therapy for Staphylococcus aureus bacteremia.头孢唑林治疗金黄色葡萄球菌菌血症。
Clin Infect Dis. 2005 Jul 1;41(1):127. doi: 10.1086/430833.
8
Impact of an assay that enables rapid determination of Staphylococcus species and their drug susceptibility on the treatment of patients with positive blood culture results.快速鉴定葡萄球菌菌种及其药敏试验检测对阳性血培养患者治疗的影响。
Infect Control Hosp Epidemiol. 2010 Oct;31(10):1043-8. doi: 10.1086/656248.
9
Clinical Practice Variation Among Adult Infectious Disease Physicians in the Management of Staphylococcus aureus Bacteremia.成人感染病医师在金黄色葡萄球菌菌血症管理方面的临床实践差异。
Clin Infect Dis. 2019 Jul 18;69(3):530-533. doi: 10.1093/cid/ciy1144.
10
Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin.金黄色葡萄球菌菌血症的临床结局与万古霉素最低抑菌浓度之间的矛盾关系。
Clin Infect Dis. 2009 Apr 1;48(7):997-8. doi: 10.1086/597359.
本文引用的文献
1
Impact of Clopidogrel on Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: a National Retrospective Cohort Study.抗血小板药物氯吡格雷对金黄色葡萄球菌菌血症患者临床结局的影响：一项全国回顾性队列研究。
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0211721. doi: 10.1128/aac.02117-21. Epub 2022 Apr 13.
2
Ticagrelor Increases Platelet-Mediated Staphylococcus aureus Killing, Resulting in Clearance of Bacteremia.替卡格雷增加血小板介导的金黄色葡萄球菌杀伤作用，从而清除菌血症。
J Infect Dis. 2021 Nov 16;224(9):1566-1569. doi: 10.1093/infdis/jiab146.
3
Risk of infectious events in acute myocardial infarction patients treated with ticagrelor or clopidogrel.替格瑞洛或氯吡格雷治疗的急性心肌梗死患者发生感染事件的风险。
Eur J Intern Med. 2021 Mar;85:121-123. doi: 10.1016/j.ejim.2020.10.016. Epub 2020 Nov 14.
4
Clinical Outcomes Associated With the Use of Anticoagulant and Antiplatelet Agents in Patients Undergoing Treatment for Infective Endocarditis: A Pilot Study.接受感染性心内膜炎治疗的患者使用抗凝和抗血小板药物的临床结局：一项初步研究。
Clin Ther. 2020 Sep;42(9):1828-1838. doi: 10.1016/j.clinthera.2020.07.007. Epub 2020 Aug 2.
5
Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections.替卡格雷与金黄色葡萄球菌菌血症和其他感染的风险。
Eur Heart J Cardiovasc Pharmacother. 2022 Jan 5;8(1):13-19. doi: 10.1093/ehjcvp/pvaa099.
6
Effect of Ticagrelor on Reducing the Risk of Gram-Positive Infections in Patients With Acute Coronary Syndrome.替格瑞洛对降低急性冠状动脉综合征患者革兰阳性感染风险的影响。
Am J Cardiol. 2020 Sep 1;130:56-63. doi: 10.1016/j.amjcard.2020.06.016. Epub 2020 Jun 17.
7
Comparative Efficacy and Safety of Oral P2Y Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials.比较口服 P2Y 抑制剂在急性冠状动脉综合征中的疗效和安全性：来自 12 项随机试验的 52816 例患者的网络荟萃分析。
Circulation. 2020 Jul 14;142(2):150-160. doi: 10.1161/CIRCULATIONAHA.120.046786. Epub 2020 May 29.
8
Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria.替格瑞洛在常规抗血小板剂量下对耐抗生素阳性革兰氏菌的抗菌活性。
JAMA Cardiol. 2019 Jun 1;4(6):596-599. doi: 10.1001/jamacardio.2019.1189.
9
Vital Signs: Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections - United States.生命体征：耐甲氧西林和甲氧西林敏感金黄色葡萄球菌血流感染的流行病学和近期趋势 - 美国。
MMWR Morb Mortal Wkly Rep. 2019 Mar 8;68(9):214-219. doi: 10.15585/mmwr.mm6809e1.
10
Prophylaxis of experimental endocarditis with antiplatelet and antithrombin agents: a role for long-term prevention of infective endocarditis in humans?抗血小板和抗凝血药物预防实验性心内膜炎：在人类中是否可长期预防感染性心内膜炎？
J Infect Dis. 2015 Jan 1;211(1):72-9. doi: 10.1093/infdis/jiu426. Epub 2014 Aug 1.
Zotero 插件